ecancermedicalscience

Research

A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

29 Sep 2022
Annie Kanchan Baa, Atul Sharma, Suman Bhaskar, Ahitagni Biswas, Sacchidanand Jee-Bharti, Alok Thakar, Rajeev Kumar, Raja Pramanik

Background: Head and neck squamous cell carcinoma (HNSCC) is a huge burden in India with the majority of patients presenting in advanced unresectable stages. Innovative, low-cost but efficacious regimens that can be easily administered in the outpatient setting are the need of the hour. We envisaged assessing whether a readily available triplet therapy of erlotinib + methotrexate + 5-fluorouracil (EMF) is efficacious in terms of extending life and maintaining the quality of life in such patients.

Patients and methods: This was a single-arm, phase II, investigator-initiated interventional study. Thirty-five platinum-resistant/refractory patients of HNSCC were treated with a combination of erlotinib 150 mg, methotrexate 40 mg/m2 (d1, d8) and 5-fluorouracil 500 mg/m2 (d1, d8) every 28 days till progression or unacceptable toxicities. The primary endpoint was overall response rates (ORRs) at 3 months; additional endpoints were disease control rate (DCR) at 3 months, overall survival (OS) and progression-free survival (PFS), safety and patient-reported quality of life.

Results: The ORR and DCR at 3 months were 45.7% and 68.5%, respectively. The PFS was 5 months (95% confidence interval (95% CI): 3.9–6 months) and the OS was 9 months (95% CI: 7.4–10.5 months). The 3- and 6-month PFS rates were 86% ± 6% and 45% ± 9%, respectively, while the OS rates at 3 and 6 months were 91% ± 5% and 68% ± 8%, respectively. Rash, mucositis and fatigue were common adverse events occurring in 23 (65%), 14 (40%) and 9 (25.7%), respectively. The most common grade 3 events seen were rash in 5 (14.2%) and diarrhoea in 2 (5.7%). Clinically significant improvement from baseline was seen in many domains of Quality of Life Core Questionnaire and Quality of Life Head and Neck Module.

Conclusions: The triplet regimen of EMF is a feasible and safe therapeutic option in patients with platinum-resistant/refractory HNSCC. It has demonstrated favourable response rates and improvement in quality of life; however, a randomised phase III study would add more robust value (NCT: CTRI/2020/02/023378).

Related Articles

Arunangshu Ghoshal, Anjum Khan Joad, Odette Spruijt, Shobha Nair, MR Rajagopal, Firuza Patel, Anuja Damani, Jayita Deodhar, Dinesh Goswami, Geeta Joshi, Savita Butola, Charu Singh, Seema Rajesh Rao, Madhura Bhatwadekar, Mary Ann Muckaden, Sushma Bhatnagar
Arunangshu Ghoshal, Anuja Damani, MaryAnn Muckaden, Pallavi Singh, Jayita Deodhar, Sumita Mohanty, Vidya Viswanath, Amit Grover, Priti Sanghavi, Sushma Bhatnagar
Julia Downing, Eve Namisango, Stephen Connor, Patricia Batanda, Lisa Christine Irumba, Berna Basemera, Alfred Jatho, Sylvia Nakami, Harriet Nalubega, Antonia Kamate, Dianah Basirika, Joyce Zalwango, Mable Nammudu, Wedzerai Chiyoka, Francis Kayondo, David Byaruhanga, Eugene Rusanganwa, Helena Davis, Stephen Watiti, Babe Gaolebale, Lacey N Ahern, Lydia Thomas, Emmanuel Luyirika
Marina Junqueira de Almeida, Marcos Pedro Guedes Camandaroba, Antonio Paulo Nassar Jr, Victor Hugo Fonseca de Jesus
Deevyashali Parekh, Vijay M Patil, Kavita Nawale, Vanita Noronha, Nandini Menon, Sucheta More, Supriya Goud, Srushti Jain, Vijayalakshmi Mathrudev, Zoya Peelay, Sachin Dhumal, Shweta Jogdhankar, Kumar Prabhash